Navigation Links
Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer
Date:4/3/2012

ng the compound have a lower rate of relapse," said Dr. Elizabeth Mittendorf, senior author on the study and Principal Investigator for the trial.  "These studies help us to understand at a mechanistic level how the vaccine is working and on a more general level what hallmarks to look for in developing successful cancer immunotherapy."

About AE37 and Ii-Key Hybrid Platform Technology

Antigen Express is a platform technology and product-based company developing proprietary vaccine formulations for large, unmet medical needs. The Company's Ii-Key Hybrid technology platform entails the modification of fragments of antigens to increase their potency in stimulating critical members of the immune response, known as CD4+ T helper cells. Incorporating the Ii-Key modification along with tumor-associated antigens can greatly enhance the immune system's ability to recognize and destroy cancer cells bearing any of the targeted antigens as well as increasing immunological memory.

The first product candidate utilizing the Company's novel Ii-Key Hybrid technology platform is a HER-2/neu Peptide Vaccine (AE37). This "off-the-shelf" cancer immunotherapy product candidate is easier and less costly to produce than comparable cell-based approaches. AE37 is derived from a peptide fragment of the human epidermal growth factor receptor 2 (HER2) oncoprotein, which is expressed in a variety of tumors including 75-80% of breast cancers as well as a high percentage of prostate, ovarian and other cancers. AE37 represents the only HER2-based peptide vaccine currently being studied in a randomized trial and its use is not restricted to patients with a particular type of human leukocyte antigen (HLA) peptide.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery o
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Generex Announces Patent Award for its Core Vaccine Technologies in Japan
2. Generex Secures Commitments for $3.6M Capital Raise
3. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
4. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
5. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
6. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
7. Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting
8. Generex Provides Update on Spinout of Antigen Express
9. Generex Augments Cash Position With Sales of Non-Essential Assets
10. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
11. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... May 6, 2015   University of Maryland (UM) ... today the signing of an exclusive option by Biomecite ... (UMB) to develop diagnostics to detect inflammatory bowel diseases ... (CD). Drs. Florian Fricke and James ... with the University of Maryland School of Medicine,s Institute ...
(Date:5/6/2015)... May 6, 2015 ... specialist, announced today that it has signed an agreement ... PEIX ) for the delivery of an industrial scale ... the consumption of water, energy and emissions ... This project is fully aligned ...
(Date:5/5/2015)... Frederick, MD (PRWEB) May 05, 2015 ... solutions provider released FreezerPro® version 7, the latest major ... management software., Upgrade is a ... Revamped UI succeeds in enhancing users experience, while also ... overall performance, reduces system requirements , Download ...
(Date:5/5/2015)...  23andMe, Inc., the leading personal genetics company, today ... in collaboration with Pfizer Inc. The companies aim ... commonly known as lupus, into the study to help ... also in collaboration with the Lupus Research Institute, and ... Approximately 1.5 million people in the U.S. suffer ...
Breaking Biology Technology:Biomecite Diagnostics Signs Option Agreement with UM Baltimore to Develop Tools to Detect Inflammatory Bowel Diseases 2Biomecite Diagnostics Signs Option Agreement with UM Baltimore to Develop Tools to Detect Inflammatory Bowel Diseases 3Whitefox Signs Agreement With Pacific Ethanol Inc. 2RURO Releases version 7 of FreezerPro® software 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 3
... 2011 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: ... that the United States Patent and Trademark Office (USPTO) has ... D and Fam3C are Biomarkers for Alzheimer,s Disease."  The patent ... as combinations that include these biomarkers. "This patent ...
... and HONG KONG, May 25, 2011 SuperNova ... human and non-human health applications, today announced it ... Valley Association of Startup Entrepreneurs (SVASE) annual Launch: ... campus on Tuesday, June 7, 2011 at 1:15 ...
... Otonomy, Inc., a clinical stage biopharmaceutical company ... the inner and middle ear, today announced the ... operations officer.  Mr. Wroblewski brings the company broad ... supply chain management, packaging and quality assurance.  At ...
Cached Biology Technology:Vermillion Announces Notice of Allowance for Alzheimer Patent 2Vermillion Announces Notice of Allowance for Alzheimer Patent 3SuperNova Diagnostics® Selected to Present at Launch: Silicon Valley 2011 2Otonomy Appoints Gerald Wroblewski as Chief Operations Officer 2Otonomy Appoints Gerald Wroblewski as Chief Operations Officer 3
(Date:4/13/2015)... According to a recently ... & Opportunities, 2020", the global biometrics market is ... till 2020. The biometrics market is garnering attention ... review of biometric management systems. The constant development ... greater efficiency, are resulting in increasing installation of ...
(Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
(Date:4/2/2015)... 2015 According to preliminary estimates ... somewhat higher than 125 MSEK. This exceeds the guidance ... that revenues for Q1 2015 would be in line ... Q4 2014. The operating result for the first quarter ... interim report will as previously communicated be published on ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Revises Revenues for Q1 2015 2
... translations of a basic research discovery into a promising ... be discussed publicly for the first time by the ... Dec. 14, at the American Society for Cell Biology ... is Progeria, or Hutchinson-Gilford Progeria Syndrome (HGPS), a rare, ...
... Practice as well as sleep may help birds learn ... during sleep helps young songbirds to develop the vocal ... have found. Sleep is well known to ... processes studied in humans, including acquiring complex skills such ...
... Search & Match,the leading provider of high-performance search ... joined the company as Product Marketing Manager. , ... years of product and marketing management,experience to the ... high-tech products and solutions worldwide. He has deep ...
Cached Biology News:In just 5 years, gene discovery to clinical trial of potential treatment 2In just 5 years, gene discovery to clinical trial of potential treatment 3In just 5 years, gene discovery to clinical trial of potential treatment 4Practice as well as sleep may help birds learn new songs 2Practice as well as sleep may help birds learn new songs 3
Mouse monoclonal antibody raised against a partial recombinant MYO7A. NCBI Entrez Gene ID = MYO7A...
... Cell Lines ,High Quality, Functionally-Validated, Ion Channel ... known for having a critical role in ... a key function in pain, CNS and ... have been investigated in therapeutic areas, such ...
Mouse monoclonal antibody raised against a partial recombinant TTC3. NCBI Entrez Gene ID = TTC3...
Mouse polyclonal antibody raised against a partial recombinant SYT4. NCBI Entrez Gene ID = 6860...
Biology Products: